publication venue for
- Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.. 10:342-352. 2024
- Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. 10:201-209. 2024
- Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation. 9:208-219. 2023
- Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent. 8:847-856. 2022
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. 8:786-795. 2022
- Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. 8:825-836. 2022
- Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. 8:648-659. 2022
- Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. 8:695-706. 2022
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. 8:462-473. 2022
- The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. 8:253-262. 2022
- Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. 7:e71-e71. 2021
- Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation. 7:251-260. 2021
- New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. 6:301-309. 2020
- External applicability of the COMPASS trial: the Western Denmark Heart Registry. 5:192-199. 2019
- Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. 5:64-69. 2019
- Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. 5:70-79. 2019